Roles of transient receptor potential channel 6 in glucose-induced cardiomyocyte injury

Table 1 Blood glucose levels in control and streptozotocin injection groups (mmo/L)

Group	n	0 wk	1 wk	4 wk	8 wk	12 wk
Control	10	6.3 ± 0.6	6.8 ± 0.6	6.7 ± 0.5	6.5 ± 0.3	6.4 ± 0.9
STZ	10	6.1 ± 0.5	16.1 ± 8.2	14.6 ± 3.8	19.2 ± 5.7a,b	23.4 ± 4.3a,b

^aP < 0.001, compared with that before modeling.

^bP < 0.001, compared with the control group.

STZ: Streptozotocin.

Table 2 Comparison of cardiac ultrasound results between control and streptozotocin injection groups in left ventricular end diastolic diameter, left ventricular end systolic diameter, left ventricular ejection fraction, and fraction shortening

Group	n	LVEDD (mm)	LVESD (mm)	LVEF (%)	LVFS (%)
Control	10	2.9 ± 0.4	0.95 ± 0.3	82 ± 2.1	67 ± 2.9
STZ	10	3.6 ± 0.3a	0.81 ± 0.5a	69 ± 3.2b	48 ± 1.8c

Compared with the control group:

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

STZ: Streptozotocin; LVEDD: Left ventricular end diastolic diameter; LVESD: Left ventricular end systolic diameter; LVEF: Left ventricular ejection fraction; LVFS: Left ventricular fraction shortening.

Table 3 Detection of myocardial injury markers in control and streptozotocin injection groups

Group	n	LDH (mU/mg)	CK-MB (U/g)	SOD (U/mg)
Control	10	424.7 ± 5.2	11.3 ± 0.5	67.5 ± 2.3
STZ	10	1027.6 ± 4.3a	48.2 ± 0.6a	19.8 ± 1.2a

Compared with the control group:

^aP < 0.0001.

STZ: Streptozotocin; LDH: Lactate dehydrogenase; SOD: Superoxide dismutase.